Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announces that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).
Read the full article: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio //
Source: https://www.globenewswire.com/news-release/2024/04/03/2856591/0/en/Genmab-to-Broaden-and-Strengthen-Oncology-Portfolio-with-Acquisition-of-ProfoundBio.html